128 related articles for article (PubMed ID: 36215154)
1. Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma.
Ma G; Gao Y; Jing X; He C; Liu H; Wu X; Gao Z; Li Y; Zhang S; Zhao G
Leuk Lymphoma; 2023 Jan; 64(1):140-150. PubMed ID: 36215154
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
[No Abstract] [Full Text] [Related]
3. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
4. Relationship between the absolute lymphocyte count/absolute monocyte count ratio, soluble interleukin 2 receptor level, serum programmed cell death 1 level, and the prognosis of patients with diffuse large B-cell lymphoma.
Li C; Li W; Xu G; You M; Wu W; Kuang L
Ann Palliat Med; 2021 Oct; 10(10):10938-10945. PubMed ID: 34763456
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
[TBL] [Abstract][Full Text] [Related]
6. Mutational profiling of circulating tumor DNA and clinical characteristics in lymphoma: Based on next generation sequencing.
Hou Y; Zi J; Liu S; Ge Q; Ge Z
Mol Carcinog; 2023 Feb; 62(2):200-209. PubMed ID: 36300887
[TBL] [Abstract][Full Text] [Related]
7. Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.
Juskevicius D; Jucker D; Klingbiel D; Mamot C; Dirnhofer S; Tzankov A
J Hematol Oncol; 2017 Mar; 10(1):70. PubMed ID: 28302137
[TBL] [Abstract][Full Text] [Related]
8. Infused Autograft Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched Case-Control Study.
Porrata LF; Burgstaler EA; Winters JL; Jacob E; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Villasboas J; Paludo J; Markovic SN
Transplant Cell Ther; 2021 Sep; 27(9):769.e1-769.e8. PubMed ID: 34091071
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.
Zhu Y; Fu D; Shi Q; Shi Z; Dong L; Yi H; Liu Z; Feng Y; Liu Q; Fang H; Cheng S; Wang L; Tian Q; Xu P; Zhao W
Front Immunol; 2022; 13():842439. PubMed ID: 35401516
[TBL] [Abstract][Full Text] [Related]
10. SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.
Guo B; Huang Y; Duan Y; Liao C; Cen H
Cancer Med; 2022 Mar; 11(5):1281-1291. PubMed ID: 35106936
[TBL] [Abstract][Full Text] [Related]
11. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
[TBL] [Abstract][Full Text] [Related]
12. [Mutational Spectrum and Prognosis Analysis of Young Patients with Diffuse Large B-Cell Lymphoma Based on Next-Generation Sequencing].
Lyu LY; Nie YL; Renaguli A; Qi XL; Muhebaier A; Zhai SS; An L; Mao M; Li Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):403-410. PubMed ID: 37096512
[TBL] [Abstract][Full Text] [Related]
13. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
[TBL] [Abstract][Full Text] [Related]
14. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of
Qin Y; Chen H; Liu P; Zhang C; Yang J; Gui L; He X; Zhou L; Zhou S; Jiang S; Jiang H; Shi Y
Cancer Biol Med; 2021 Nov; 19(6):893-909. PubMed ID: 34806851
[TBL] [Abstract][Full Text] [Related]
16. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
17. Molecular Biomarker Exploration of Rituximab plus CHOP Therapy in Real-World Diffuse Large B-Cell Lymphoma Patients.
Wang H; Lin Y; Li Z; Wu Y; Yang Z; Gao S; Lin F
Clin Lab; 2023 Jan; 69(1):. PubMed ID: 36649512
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.
Li YL; Gu KS; Pan YY; Jiao Y; Zhai ZM
BMC Cancer; 2014 May; 14():341. PubMed ID: 24884604
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics and prognosis of primary Waldeyer's ring and lymph node diffuse large B-cell lymphoma in the rituximab era.
Jing XM; Yu JR; Luo YK; Zhang SC; Liu JF; Li L; Wu P; Zhang ZH
Leuk Res; 2017 Sep; 60():89-93. PubMed ID: 28772206
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
[Next] [New Search]